时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
However, these improvements have coexisted with persistent socioeconomic and territorial inequalities in incidence, mortality, and survival, driven by disparities in timely access to diagnosis and treatment (–).；Nevertheless, mammography coverage remains below that observed in countries of the Organization for Economic Co-operation and Development (OECD), highlighting ongoing challenges in achieving effective, equitable, population-based screening ().；Despite the leading role of AUGE/GES in structuring oncologic care in Chile, robust evidence isolating its specific contribution to changes in breast cancer mortality—independent of pre-existing secular trends and concurrent health system transformations—remains limited.
方法
We included all registered female deaths attributed to breast cancer using ICD-9 (1990-1997) and ICD-10 (1997-2024) from official data (1990 to 2022) and from preliminary death records 2023–2024 (ICD codes in the ).；We applied interrupted time series models (, ) using negative binomial regression () to account for overdispersion in mortality counts.；Statistical significance was assessed at α = 0.05.；This study used aggregated secondary data and did not involve human participants.
核心结论
Among women, breast cancer mortality increased markedly after age 50, with approximately 80% of female deaths occurring in women aged 50 years and older.；No abrupt changes or discontinuities are observed around either 1995 or 2004 in crude indicators.；This divergence indicates that the observed increase in crude mortality is primarily attributable to population aging, rather than to an increase in age-specific risk of dying from breast cancer. ‖ 结论：OECD syntheses also highlight that mortality trajectories for several cancers (including breast cancer) can diverge across health systems depending on prevention, early detection, and treatment organization (, ).
局限
However, age-stratified analyses revealed heterogeneity: women aged 65–69 years and those aged ≥80 years experienced more pronounced declines after 2005, without a comparable change around 1995.；Future studies should therefore examine this population separately and incorporate stage at diagnosis, molecular subtype, diagnostic delay, treatment completion, and long-term survival.；Mammography use in Chile also exhibits persistent socioeconomic gradients, limiting the potential mortality impact in the absence of organized and equitable screening coverage ().
对本项目的价值
★☆☆☆☆ 相关范围内，作为背景与横向对照收录。
全文来源
PMC JATS 全文（正文 25,523 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Impact of Chile's Explicit Health Guarantees Policy on breast cancer mortality: an interrupted time series analysis (1990-2024).
- 期刊与标识：Front Oncol · PMID 42948037 · DOI 10.3389/fonc.2026.1801070
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。